摘要:
At least one object of the present invention to provide a novel compound. A compound represented by Chemical Formula (i):
wherein a bond indicated by parallel broken and solid lines represents a single bond or a double bond capable of taking a cis configuration or a trans configuration, R1 and R2 each represent hydrogen, an alkyl group having 1 to 6 carbon atoms, a cycloalkyl group having 3 to 8 carbon atoms, an aryl group having 6 to 8 carbon atoms, or R4-C(=O)-, and R4 represents an alkyl group having 1 to 6 carbon atoms, R3 represents hydrogen, an alkyl group having 1 to 6 carbon atoms, a cycloalkyl group having 3 to 8 carbon atoms, or an aryl group having 6 to 8 carbon atoms.
摘要:
The subject of the invention is a process for the preparation of high purity prostaglandin acid of the general formula II wherein the bonds marked with dotted lines represent single or double bonds wherein the double bonds may be cis- or trans oriented, Y represents 0 or CH 2, and R3 stands for a phenyl group which is optionally substituted with CF3, wherein the crude prostaglandin acid of the general formula II is purified by normal phase silicagel chromatography.
摘要:
Prostaglandin nitroderivatives having improved pharmacological activity and enhanced tolerability are described. They can be employed for the treatment of glaucoma and ocular hypertension.
摘要:
The subject of the invention is process the preparation of travoprost of formula (I) characterized by that the free acid of formula (II) is a.) activated with 2-chloro-1,3-dimethyl-imidazolinium chloride (DMC) and the resulting activated carboxylic acid intermediate is reacted with isopropyl alcohol, or b.) reacted with alkyl haloformate and the resulting mixed anhydride is reacted with isopropyl alcohol, or c.) activated with a straight or branched C1-8 dialkyl dicarbonate and reacted with isopropanol in the presence of water-free magnesium salt.
摘要:
Novel processes for the preparation of a compound of Formula I-2 substantially free of the 5,6- trans isomer:
wherein
R 2 , R 3 and R 4 are as defined in the specification are provided. Novel intermediates for the preparations of isomer free Prostaglandins and derivatives thereof are also provided.